Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation

Background/Aims: A meta-analysis was undertaken to as- sess the effect of triptorelin 11.25 mg 3-month prolonged- release formulation in central precocious puberty (CPP). Methods: All available clinical studies with triptorelin 11.25 mg were included. The primary outcome was the proportion of children with suppressed luteinising hormone (LH) re- sponse (peak LH ≤3 IU/L) to the gonadotrophin-releasing hormone (GnRH) test 3 months after triptorelin 11.25 mg in- jection. Secondary outcomes included: the proportion with suppressedpeakLHresponseat6monthsandthepropor- tion with suppressed peak follicle-stimulating hormone (FSH) response (≤3 IU/L), suppressed oestradiol (≤20 pmol/L) in girls or suppressed testosterone (≤30 ng/dL) in boys at 3 months. Results: 153 children (13 boys, 140 girls) were in- cluded. The proportion with a suppressed peak LH response to the GnRH test was 87.6% (95% CI: 81.3–92.4, p < 0.0001, for a proportion >70%) and 92.8% (95% CI: 87.5–96.4, p < 0.0001, for a proportion >70%) at 3 and 6 months, respec-
tively. FSH peak, oestradiol, and testosterone were sup- pressed in 86.7% (95% CI: 79.1–92.4), 97.1% (95% CI: 91.6– 99.4), and 72.7% (95% CI: 39.0–94.0) of children at 3 months, respectively. Conclusion: Triptorelin 11.25 mg 3-month for- mulation is efficacious in suppressing LH peak and other go- nadal hormones and in slowing the progression of CPP in children.

Show PDF